vivoPharm Selects Provantis® to Automate GLP Research for Australian Market
CRO Leverages Provantis to Tap into Australia's Unmet Need for Local GLP Compliant Services
CONSHOHOCKEN, PA – October 27, 2016 - Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that vivoPharm Asia/Pacific, an Australian based contract research laboratory, has purchased Instem’s Provantis® preclinical data management solution. The purchase was made to support the company’s Melbourne, Australia team in their GLP (Good Laboratory Practices) research, enabling them to automate and streamline processes and improve data integrity, while maintaining GLP compliance. In addition, by harnessing Instem’s SaaS deployment model, vivoPharm will benefit from lower infrastructure and support costs, together with the flexibility and scalability to meet changing business demands.
vivoPharm offers a unique, proprietary suite of services and bioanalytical technology for the biotechnology and pharmaceutical industry. The company specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug Applications (IND) filings.
- vivoPharm conducted a competitive evaluation and selected Provantis for its ease of use and robust functionality
- Under a three-year agreement, vivoPharm will be utilizing Provantis Pathology, General Toxicology, Clinical Pathology and Data Import modules.
- vivoPharm is maintaining an aggressive implementation schedule and leveraging Instem’s SaaS deployment option to more rapidly meet the growing demands of the Australian market
- Provantis replaces labor intensive manual processes and an internally developed solution
Dr. Ralf Brandt (PhD), CEO and managing director, vivoPharm, commented, “The purchase of Provantis aligns with our comprehensive strategy to address the outsourcing needs of the burgeoning Australian and global market. We are the market leaders because we optimize our services and leverage technology to gain efficiency and improve data integrity for our customers. Provantis will help us to do both of these things as we continue to tackle the growing need for GLP compliant services in the Australian biopharmaceutical market.”
Neil Donaldson, Instem’s vice president of sales for Europe & Asia, added, “vivoPharm is an innovative and agile team. Their selection of Provantis illustrates their eagerness to maintain market leadership in this arena and reflects their deep understanding of the GLP compliance needs of their customers.”
Provantis is a fully integrated Windows-based solution suite designed to streamline activities supporting non-clinical evaluation studies in both GLP and non-GLP environments. A comprehensive and intuitive system, Provantis is in use by leading research and development organizations across the life sciences spectrum.
vivoPharm provides proprietary preclinical services with focus on Oncology, offering integrated service in different disease areas to the biotechnology and pharmaceutical industries. vivoPharm is leading in orthotopic and metastases tumor models and offers whole body imaging. Furthermore, vivoPharm provides all services including toxicology testing and bioanalytical analysis to GLP. vivoPharm’s team of highly trained specialists provides advice and optimized study design to its clients. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug Applications (IND) filing. vivoPharm operations follow strict quality control methods and meet the highest industrial standards, acknowledged by customers worldwide.
For further information please visit www.vivopharm.com
Instem is a leading supplier of IT applications and services to the early development healthcare market delivering compelling solutions for data collection, analysis and regulatory submissions management. Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions and consulting services increases client productivity by enhancing product development processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.
Gary Mitchell (US HQ)
Julie Jones (UK HQ)
Tel: +44 (0) 1785 825600